Medical systems and methods of use

• US 9,962,112 B2
• Filed: 07/16/2007
• Issued: 05/08/2018
• Est. Priority Date: 07/21/2006
• Status: Active Grant

• Current Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Original Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Inventors: Chase, H. Peter
• Primary Examiner(s): FLICK, JASON E
• Application Number:
  US12/373,888
• Publication Number:
  US 20100056993A1
• Time in Patent Office: 3,949 Days
• Field of Search: 604 66
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61M 2005/14208 with a programmable infusion control system, characterised by the infusion program
• CPC Class Codes: A61M 2205/3523 using telemetric means
• CPC Class Codes: A61M 5/14244 adapted to be carried by the patient, e.g. portable on the body
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00

Abstract

This invention provides ambulatory medical systems that include a monitoring device, a therapeutic substance administering device, and a receiver-controller for receiving a signal generated by the monitoring device and controlling the therapeutic substance administering device based on the information received from the monitoring device. The invention also provides methods for using the same.

Claims

1. A medical system comprising:

a monitoring device comprising an electronic control circuitry that is configured to monitor a rate of change in a selected state of a subject, wherein said monitoring device further comprises a telemetry system;

a therapeutic substance delivery device comprising an electronic control circuitry that is configured to deliver insulin to the subject; and

a receiver-controller device comprising an electronic circuitry that is configured to receive a signal generated by said monitoring device and is further configured to control the operation of said therapeutic substance delivery device based on the rate of change in the selected state of the subject as monitored by said monitoring device wherein said receiver-controller is configured to reduce or stop administering insulin then the glucose level decreases and to automatically resume delivery of insulin about 1 hour to about 2 hours after insulin delivery is reduced or stopped.

2. The medical system of claim 1, wherein said monitoring device monitors the rate of glucose level change in the subject.

3. The medical system of claim 2, wherein said therapeutic substance delivery device is configured to administer insulin to the subject based on the rate of glucose level change.

4. The medical system of claim 3, wherein said receiver-controller is configured to reduce or stop administering insulin when the glucose level decreases at a rate of 2 mg/dl-min or higher.

5. The medical system of claim 1, wherein said monitoring device measures the rate of subcutaneous glucose level change.

6. The medical system according to claim 1 further comprising an alarm system for providing a signal to the patient, wherein said receiver-controller is configured to reduce or stop administering insulin after a subject has been signaled by said alarm system and the subject has failed to take action responsive to said alarm.

7. The medical system according to claim 6 wherein said receiver-controller is configured to reduce or stop administering insulin after a subject has been signaled by said alarm system and the subject has failed to take action responsive to said alarm, wherein the delay to allow subject action following the signal is selected from the group consisting of about 10 minutes, about 20 minutes, about 30 minutes and about 1 hour.

8. The medical system of claim 1 wherein said receiver-controller is configured to automatically resume delivery of insulin according to the insulin sensitivity of the subject.

9. The medical system of claim 1 wherein said receiver-controller is configured to reduce or stop administering insulin to the subject when the glucose level is about 150 mg/dl or lower and the glucose level decreases at a rate of about 2 mg/dl-min or higher, the glucose level is from about 100 mg/dl to about 130 mg/dl and the glucose level decreases at a rate of from about 1 to about 2 mg/dl-min or higher, or the glucose level is about 70 mg/dl or lower.

10. The medical system of claim 1, wherein said receiver-controller is configured to reduce or stop administering insulin when the glucose level is about 70 mg/dl or lower.

11. A medical system comprising:

a monitoring device comprising an electronic control circuitry that is configured to monitor a rate of change in a selected state of a subject, wherein said monitoring device further comprises a telemetry system;

a therapeutic substance delivery device comprising an electronic control circuitry that is configured to deliver insulin to the subject;

a receiver-controller device comprising an electronic circuitry that is configured to receive a signal generated by said monitoring device and is further configured to control the operation of said therapeutic substance delivery device based on the rate of change in the selected state of the subject as monitored by said monitoring device; and

an alarm system in communication with the receiver-controller for providing a signal to the patient, wherein said receiver-controller is configured to reduce or stop administering insulin to the subject when the glucose level decreases and after the subject has been signaled by said alarm system and the subject has failed to take action within at least about 10 minutes responsive to said alarm signal.

12. The medical system of claim 11 wherein the period of time that the subject has failed to take action is selected from the group consisting of about 10 minutes, about 20 minutes, about 30 minutes, and about 1 hour.

13. The medical system of claim 11, wherein said monitoring device monitors the rate of glucose level change in the subject.

14. The medical system of claim 11, wherein said monitoring device monitors the rate of subcutaneous glucose level change.

15. The medical system of claim 11 wherein said receiver-controller is configured to automatically resume delivery of insulin according to the insulin sensitivity of the subject.

16. The medical system of claim 11, wherein said receiver-controller is configured to reduce or stop administering insulin when the subject has failed to take action within at least about 10 minutes responsive to said alarm signal and the glucose level is about 150 mg/dl or lower and the glucose level decreases at a rate of about 2 mg/dl-min or higher, the glucose level is about 130 mg/dl or lower and the glucose level decreases at a rate of from about 1 to about 2 mg/dl-min or higher, or the glucose level is about 70 mg/dl or lower.

17. A medical system comprising:

a monitoring device comprising an electronic control circuitry that is configured to monitor the rate of glucose level change in a subject, wherein said monitoring device further comprises a telemetry system;

a therapeutic substance delivery device comprising an electronic control circuitry that is configured to deliver insulin to the subject; and

a receiver-controller device comprising an electronic circuitry that is configured to receive a signal generated by said monitoring device and is further configured to control the operation of said therapeutic substance delivery device based on the rate of change in the selected state of the subject as monitored by said monitoring device wherein said receiver-controller is configured to reduce or stop administering insulin when the glucose level decreases and to automatically resume delivery of insulin according to the insulin sensitivity of the subject.

18. The medical system of claim 17, wherein said monitoring device monitors the rate of subcutaneous glucose level change.

19. The medical system of claim 17, wherein said receiver-controller is configured to reduce or stop administering insulin when the glucose level about 150 mg/dl or less and the glucose level decreases at a rate of about 2 mg/dl-min or higher.

20. The medical system of claim 17, wherein said receiver-controller is configured to reduce or stop administering insulin when the glucose level is about 70 mg/dl or lower.